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Human Immunodeficiency Virus and the Prevalence of
Undiagnosed Tuberculosis in African Gold Miners
Elizabeth L. Corbett, Salome Charalambous, Vicky M. Moloi, Katherine Fielding, Alison D. Grant, Christopher
Dye, Kevin M. De Cock, Richard J. Hayes, Brian G. Williams, and Gavin J. Churchyard
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom; Biomedical
Research and Training Institute, Harare, Zimbabwe; Aurum Health Research, Westvaal Hospital, Orkney, South Africa; and Communicable
Diseases Cluster, World Health Organization, Geneva, Switzerland
We hypothesized that rapid presentation may be a general feature
of tuberculosis (TB) associated with human immunodeficiency virus
(HIV) that limits the impact of HIV on the point prevalence of TB.
To investigate this, we performed a cross-sectional HIV and TB
disease survey with retrospective and prospective follow-up. HIV
prevalence among 1,773 systematically recruited miners was 27%.
TB incidence was much more strongly HIV associated (incidence
rate ratio, 5.5; 95% confidence interval [CI], 3.5–8.6) than the point
prevalence of undiagnosed TB disease (odds ratio, 1.7; 95% CI,
0.9–3.3). For smear-positive TB, 7 of 9 (78%) prevalent cases were
HIV negative, and point prevalence was nonsignificantly lower in
miners who were HIV positive (odds ratio, 0.8; 95% CI, 0.1–4.2).
The calculated mean duration of smear positivity before diagnosis
(point prevalence/incidence) was substantially shorter for HIV-posi-
tive than HIV-negative TB patients (0.17 and 1.15 years, respectively;
ratio, 0.15; 95% CI, 0.00–0.73). HIV has considerably less impact on
the point prevalence of TB disease than on TB incidence, probably
because rapid disease progression increases presentation and case-
finding rates. The difference in mean duration of smear positivity
was particularly marked and, if generalizable, will have major implica-
tions for TB control prospects in high HIV prevalence areas.
Keywords: Africa; epidemiology; human immunodeficiency virus; prev-
alence; tuberculosis
The mean duration of infectiousness is one of the key determi-
nants of the dynamics of infectious disease epidemics: shortening
this period will tend to reduce the number of secondary infec-
tions generated per infectious case, hence reducing the basic
reproductive number, Ro, for that disease in that population (1).
One of the characteristic features of tuberculosis (TB) is a long
period of infectiousness (2) so that even today the mean duration
of smear positivity is estimated in years, rather than months, in
many resource-poor settings (2). The consequences include a
high point prevalence of undiagnosed TB disease relative to
incidence rates and ongoing high rates of TB transmission (2–6).
The rapid pace with which TB disease progresses in the immu-
nosuppressed is well described (7–10). In our study site of South
African gold miners, TB incidence increased greatly during the
1990s because of the human immunodeficiency virus (HIV) epi-
demic (11), but with relatively little change in the point prevalence
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of radiologically active TB detected at routine annual fitness exam-
ination (Figure 1). A mining hospital and several primary clinics
provided free diagnostic investigations and healthcare for the
study workforce (12). TB is an occupational disease of gold
miners and is compensatable in South Africa. Because of this,
awareness of TB among mining healthcare workers was likely
to have been high even before the HIV epidemic. The changing
relationship between incident and prevalent TB disease was
apparent from the start of the HIV epidemic in the early 1990s
and could not be readily attributed to changes in TB control
policy or diagnostic practices or to more intensive follow-up of
known miners who were HIV-positive (11). From this observa-
tion, we formed the hypothesis that a previously overlooked,
but important, aspect of the natural history of HIV-associated
TB may be that the mean durations of disease activity and
infectiousness before diagnosis are greatly reduced compared
with TB in persons who are HIV-negative.
The mean duration of infectiousness can be estimated for
any given population by dividing the point prevalence of infec-
tious TB disease by the annual incidence rate (2). To estimate
HIV-specific duration of TB infectiousness in persons with no
previous TB diagnosis, we combined a cross-sectional survey for
HIV and TB disease with a longitudinal cohort study of the
same participants, all of whom were mine workers recruited
from their routine annual fitness-to-work examination. Some of
the results of these studies have been previously reported in the
form of abstracts (12, 13).
METHODS
Alternate miners attending annual fitness examinations between July
2000 and January 2001 were screened for prevalent TB with a symptoms
questionnaire and two sputum specimens for microscopy and culture, in
addition to their routine annual chest radiograph (14). Urine specimens
were taken for confidential HIV testing. Laboratory methods were as
previously described (14, 15). Participants with symptoms or abnormal
screening results were recalled for clinical examination, repeat radiogra-
phy, and sputum specimens. Smear-negative TB suspects with no re-
sponse to broad-spectrum antibiotics were started on TB treatment and
followed after 2 months.
Participants were followed retrospectively for 12 months before
their date of enrollment and prospectively to December 2001 using a
database to identify incident TB cases (11). Participants treated for TB
before the start of retrospective follow-up were excluded from further
analysis (Figure 2). Loss to employment was identified from payroll
records. A single hospital provided free treatment. A diagnostic algo-
rithm for TB based on microscopy, culture, radiography, and response
to antibiotics was in routine use and did not depend on known HIV
status (11). Miners leaving employment were screened for TB, and
death from undiagnosed TB was known to be rare (16).
Case Definitions for TB Disease
The primary analysis was based on confirmed TB disease meeting defi-
nite or probable case definitions outlined later here. Because of possible
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Figure 1. Time trends in observed new tuberculosis (TB) case-notification
rates and the point prevalence of new radiologic TB at annual screening,
also showing the progressive reduction in the ratio of these two indicators
since 1990. Serial case notification and radiologic point prevalence rates
for new TB disease are shown for the study workforce (Churchyard and
colleagues [11] and Dr. G. Churchyard, unpublished data). Recurrent
episodes of TB are not included. The gray dotted line refers to the values
shown on the right y axis and illustrates the progressive decline in the
ratio of these two indicators of TB control that has occurred during the
1990s. Minor modifications were made to the TB control program in
1995 to comply fully with the South Africa National TB Control Program,
but the program had complied with most aspects of the directly ob-
served therapy, short course (DOTS) strategy since the late 1980s (11).
p.a.  per annum.
false-positive results, definitions of prevalent TB did not rely on screen-
ing tests alone.
Prevalent TB disease—(1) definite: culture positive (five or more colo-
nies of Mycobacterium tuberculosis) from both screening and follow-
up specimens or smear and culture positive at follow-up; (2) probable:
radiologic features of TB with no response to broad-spectrum antibiot-
ics plus response to TB treatment; and (3) possible: treated for TB
but did not meet the previously mentioned definitions.
Incident TB disease—(1) definite: five or more colonies of M. tubercu-
losis from one or more specimens or two or more positive sputum
smears or one positive smear from a normally sterile site; (2) probable:
single smear positive without culture confirmation or radiologic fea-
tures of TB with no response to broad-spectrum antibiotics plus re-
sponse to TB treatment; and (3) possible: treated for TB but did not
meet the previously mentioned definitions.
Ethical Approval
Approval was given by the ethics committees of the London School of
Hygiene and Tropical Medicine, Ernest Oppenheimer Hospital, An-
glogold Health Services Medical Research Ethics Committee, and the
University of Witwatersrand, South Africa.
Data Analysis
STATA 7.0 software (STATA Corporation, College Station, TX) was
used. Follow-up was terminated at the earliest of December 2001, first
TB diagnosis, death, loss to employment (Figure 2). Poisson and logistic
regression were used for univariate and multivariate analysis of cohort
and cross-sectional data, respectively. Tests for trend were calculated
using likelihood ratio tests. Mean disease duration before diagnosis was
Figure 2. Study recruitment and exclusion criteria for each stage of the
analysis. *Of the retrospective cases, 7 (58%) of 12 HIV-negative patients
and 9 (33%) of 27 HIV-positive patients were diagnosed at the previous
annual fitness screen, with the remainder self-presenting.
estimated from point prevalence of undiagnosed TB divided by annual
incidence rates. Effects of covariates on duration of disease before
diagnosis for categoric variables were estimated as ratios of disease
duration (disease duration ratios). Bootstrap estimates of 95% confi-
dence limits were made for disease duration and disease duration ratios.
RESULTS
The baseline characteristics of 1,773 study participants are sum-
marized in Table 1, with participation rates and exclusions at
each stage of the study as summarized in Figure 2.
Point Prevalence of Previously Undiagnosed TB Disease
The point prevalence of previously undiagnosed TB disease (Table
2) among 453 participants who were HIV-positive was 3.8% (95%
confidence interval [CI], 2.2–5.9%) for all diagnosed cases, all of
whom met case definitions for definite or probable TB disease.
One patient had symptomatic TB lymphadenitis, with the re-
maining 16 patients having pulmonary or combined pulmonary
and extrapulmonary TB. Two participants who were HIV-posi-
tive had positive screening smears, giving a point prevalence of
smear-positive TB disease of 0.44% (95% CI, 0.02–1.1%).
Among participants who were HIV-negative, the point preva-
lence rates of all diagnosed and all confirmed TB disease were
2.3% (95% CI, 1.6–3.3%) and 2.2% (95% CI, 1.4–3.3%) respec-
tively. There were seven participants who were HIV-negative
with positive screening smears, giving a point prevalence of
smear-positive TB disease of 0.55% (95% CI, 0.14–0.95%).
These prevalence rates were not significantly different from
those found in miners who were HIV-positive, as shown in Table
2, which also gives odds ratios and a breakdown of the point
prevalence of confirmed TB by age and silicosis for both miners
who were HIV-positive and those who were HIV-negative.
Overall, the univariate odds ratios for HIV were 1.7 (95% CI,
0.89–3.3) for confirmed TB cases and 0.81 (95% CI, 0.082–4.2) for
smear-positive disease, although the latter estimate was based
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TABLE 1. BASELINE CHARACTERISTICS OF STUDY
PARTICIPANTS, ACCORDING TO HUMAN-
IMMUNODEFICIENCY-VIRUS STATUS
HIVve HIVve p Value
Total number 480 1,293
Age group, No. (%) 0.001
18–29 yr 50 (10%) 91 (7%)
30–39 yr 215 (45%) 488 (38%)
40–49 yr 167 (35%) 567 (44%)
 50 yr 48 (10%) 147 (11%)
Employment as a miner, No. (%) 0.001
 10 yr 118 (25%) 214 (17%)
10–19 yr 181 (38%) 474 (37%)
20–24 yr 82 (17%) 302 (23%)
 25 yr 99 (21%) 303 (23%)
Silicosis grade, No. (%)* 0.34
None (ILO 0/0) 356 (76%) 953 (75%)
Possible (ILO 0/1) 64 (14%) 184 (15%)
Probable (ILO 1/0) 24 (5%) 43 (3%)
Early (ILO 1/1) 17 (4%) 64 (5%)
Advanced (ILO 2/2 and higher) 10 (2%) 23 (2%)
No radiograph available 9 (2%) 26 (2%)
TB in preceding year, No. (%)†  0.001
Yes 27 (5.6%) 12 (0.9%)
Definition of abbreviations: HIVve  HIV-positive; HIVve  HIV-negative;
TB  tuberculosis.
* Scored from the previous annual chest radiograph. Grades correspond to ILO
grades as detailed in the METHODS section. Films were missing for 9 (1.9%) HIVve
and 26 (2.0%) HIVve participants respectively, none of whom had TB during
this study.
† These participants were not included in the cross-sectional prevalence analysis.
on only two and seven HIV-positive and HIV-negative cases,
respectively. There was an increase in the point prevalence of
confirmed TB with age in both miners who were HIV-positive
and those who were HIV-negative, with a statistically significant
TABLE 2. POINT PREVALENCE OF PREVIOUSLY UNDIAGNOSED TUBERCULOSIS DISEASE AMONG
MINERS WHO WERE HUMAN IMMUNODEFICIENCY VIRUS–NEGATIVE AND THOSE WHO
WERE HUMAN IMMUNODEFICIENCY VIRUS–POSITIVE
HIV HIV
Point Prevalence Point Prevalence Odds Ratio
No. (% ) No. (% ) (HIV) 95% CI
Smear ve TB*† 2/453 0.44% 7/1,281 0.55% 0.8 0.082–4.2
Culture ve TB† 15/453 3.3% 21/1,281 1.6% 2.1 0.98–4.2
Confirmed TB† 17/453 3.8% 28/1,281 2.2% 1.7 0.89–3.3
All diagnosed TB† 17/453 3.8% 30/1,281 2.3% 1.6 0.83–3.1
Confirmed TB
Age group‡ pT  0.006 pT  0.18
 30 yr 0/48 0% 0/91 0%
30–39 yr 5/208 2.4% 11/486 2.3%
40–49 yr 8/156 5.1% 12/562 2.1%
 50 yr 4/41 9.8% 5/142 3.5%
Silicosis§ p  0.68 p  1.00
No 15/400 3.8% 26/1,129 2.3%
Yes 2/44 4.6% 2/126 1.6%
Definition of abbreviations: CI  confidence interval; HIV  human immunodeficiency virus; PT  p value for test for trend;
TB  tuberculosis; ve  positive.
* All smear-positive cases were also culture positive for M. tuberculosis.
† All diagnosed TB includes all cases where TB treatment was started; confirmed TB includes all cases meeting definite or probable
TB case definitions (see METHODS). Smear-positive TB and culture-positive TB refer only to results from the specimens taken at the
time of prevalence screening and do not include positive follow-up specimens (see RESULTS).
‡ Age was a significant risk factor for prevalent TB in participants who were HIV-positive (test for trend p  0.006), but the trend
toward higher prevalence with older age was not significant for participants who were HIV-negative (test for trend, p  0.18).
§ Silicosis (ILO 1/0 or higher) was not a significant risk factor for prevalent TB in either participants who were HIV-positive
(p  0.68) or participants who were HIV-negative (p  1.00).
trend in participants who were HIV-positive (test for trend p 
0.006). Silicosis (ILO 1/0 or higher), however, was not a signifi-
cant risk factor for prevalent TB in participants who were either
HIV-positive (odds ratio, 1.2; 95% CI, 0.13–5.5) or HIV-negative
(odds ratio, 0.68; 95% CI, 0.08–2.8).
There was potential for negative confounding between age
and HIV status because increasing age was significantly associ-
ated with both a higher point prevalence of TB and a lower
HIV prevalence (see Tables 1 and 2). Adjusting for differences
between patients who were HIV-positive and HIV-negative in
age and silicosis gave multivariate-adjusted odds ratios for HIV
in confirmed and smear-positive TB disease, respectively, of 1.8
(1.00–3.5) and 0.9 (95% CI, 0.18–4.2).
TB Disease Incidence
There were 41 and 23 confirmed incident TB cases among the
same cohort of HIV-positive and HIV-negative participants, re-
spectively (Table 3), with the site being pulmonary in 37 (90%)
and 19 (83%) of the patients who were HIV-positive and HIV-
negative and at various extrapulmonary sites in the remainder.
There was also one additional smear-positive HIV-negative par-
ticipant who grew Mycobacterium kansasii on culture. He was
considered to have mining-associated pulmonary M. kansasii dis-
ease, not TB, and thus is not included as a case in this analysis.
TB incidence rates and univariate incidence rate ratios are shown
according to HIV status in Table 3. Incidence rates were similar
during both retrospective and prospective periods of follow-up
(incidence rate ratios 1.1 for prospective compared with retrospec-
tive periods), and thus, data were combined and analyzed together.
For confirmed TB disease, HIV infection (univariate incidence
rate ratios, 5.1; 95% CI, 3.0–9.0), silicosis, and age were each
strongly and significantly associated with incident TB disease,
as previously found in this workforce (14). TB incidence rates
increased markedly and significantly with increasing age and with
silicosis in both participants who were HIV-positive and those
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TABLE 3. INCIDENCE RATES OF TB DISEASE AMONG MINERS WHO WERE HUMAN
IMMUNODEFICIENCY VIRUS–POSITIVE AND MINERS WHO WERE HUMAN
IMMUNODEFICIENCY VIRUS–NEGATIVE
HIV HIV
Incidence per Incidence per Rate Ratio
No./PYFU 100 PYFU No./PYFU 100 PYFU (HIV) 95% CI
Smear ve TB*† 23/872 2.6 12/2,516 0.48 5.5 2.6–12.2
Culture ve TB 23/872 2.6 15/2,516 0.60 4.4 2.2–9.1
Confirmed TB† 41/872 4.7 23/2,516 0.91 5.1 3.0–9.0
All diagnosed TB cases† 52/872 6.0 29/2,516 1.15 5.2 3.2–8.5
Confirmed TB
Age group‡ pT  0.003 pT  0.008
 30 yr 2/95 2.1 1/183 0.55
30–39 yr 13/401 3.2 3/955 0.31
40–49 yr 17/298 5.7 14/1,111 1.26
 50 yr 9/78 11.6 5/267 1.87
Silicosis§ p  0.001 p  0.017
No 28/764 3.7 16/2,218 0.72
Yes 13/90 14.4 7/250 2.8
Definition of abbreviations: CI  confidence interval; HIV  human immunodeficiency virus; pT  p value for test for trend;
PYFU  person-years follow-up; TB  tuberculosis; ve  positive.
* Excludes one participant who was smear-positive and HIV-negative with probable M. kansasii disease. Seventeen of the HIV-
positive and 8 of the HIV-negative smear-positive patients were culture positive for M. tuberculosis. In the remaining cases, cultures
were either contaminated or negative or had not been requested.
† All diagnosed TB includes all cases in which TB treatment was started; confirmed TB includes all cases meeting definite or
probable TB case definitions (see METHODS).
‡ Age was a significant risk factor for incident TB in both patients who were HIV-positive (test for trend p  0.003) and those
who were HIV-negative (test for trend, p  0.008).
§ Silicosis was a significant risk factor for incident TB in both patients who were HIV-positive (p  0.001) and those who were
HIV-negative (p  0.017).
who were HIV-negative (Table 3). Excluding participants with
silicosis had only minor and nonsignificant effects on the associa-
tion with HIV (incidence rate ratios for HIV, 5.1; 95% CI, 2.7–
10.1). Adjusting for differences in age and silicosis prevalence
between participants who were HIV-positive and HIV-negative
gave multivariate-adjusted incidence rate ratios for HIV in con-
firmed and smear-positive TB disease of 5.5 (95% CI, 3.5–8.6)
and 5.9 (95% CI, 2.9–11.9), respectively.
Duration of Active TB Disease before Diagnosis
The duration of confirmed TB disease, as estimated by dividing
point prevalence by incidence, was significantly shorter for parti-
cipants who were HIV-positive (0.80 years; 95% CI, 0.42–1.35)
Figure 3. Mean TB disease duration before diagnosis by human immu-
nodeficiency virus (HIV) and smear status. The diamonds indicate the
duration before diagnosis, in years, of smear positivity (gray) and overall
TB disease activity (black) in miners who were HIV-positive and HIV-
negative; 95% confidence intervals are represented by the horizontal
lines. The difference between patients who are HIV-positive and HIV-
negative in estimated disease duration was significant for both smear-
positive and all confirmed TB disease, as indicated by disease duration
ratios (DDRs) that are significantly less than one for both comparisons.
than for participants who were HIV-negative (2.39 years; 95%
CI, 1.37–4.21). The difference for smear-positive disease was
even more pronounced with the mean duration of smear positi-
vity being 0.17 years (95% CI, 0.00–0.48) for miners who were
HIV-positive and 1.15 years (95% CI, 0.33–2.94), respectively,
as shown in Figure 3.
The ratio of duration of TB disease before diagnosis (hereaf-
ter referred to as the disease duration ratio) by HIV status was
0.33 (95% CI, 0.14–0.72) for all confirmed TB disease and 0.15
(95% CI, 0.00–0.73) for smear-positive TB disease (Figure 3).
For silicosis, the disease duration ratio was 0.22 (95% CI,
0.04–0.62) for all confirmed TB disease, indicating that TB dis-
ease also progresses significantly more rapidly in silicotics com-
pared with nonsilicotics. In contrast, older age was a significant
risk factor for both incident and prevalent TB disease and had
less effect on disease duration, with disease duration ratios rela-
tive to 18- to 39-year-olds being 0.76 (95% CI, 0.31–1.86) for
ages 40 to 49 years and 0.74 (95% CI, 0.22–2.22) for age 50 years
or older.
Potential Effects of HIV Clinic Follow-up
Neither HIV-positive nor silicotic miners had any special clinical
monitoring or follow-up at this site until an HIV care clinic was
started in 2000. This clinic provided cotrimoxazole prophylaxis
and primary isoniazid preventive therapy after screening for
active TB disease. Antiretroviral therapy did not become avail-
able until after the completion of this study. Only 4 (1%) of our
453 participants who were HIV-positive were being followed by
the HIV care clinic at the time of their prevalence screen. A
further 39 (9%) of our participants who were HIV-positive first
attended the clinic while under prospective follow-up by this
study. In total, 3 of the 41 (7%) confirmed incident TB cases in
participants who were HIV-positive were diagnosed while under
follow-up at the HIV care clinic. Thus, the potential impact of
the clinic on this study was minor and insufficient to explain the
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major differences found between miners who were HIV-positive
and HIV-negative.
DISCUSSION
This study shows that HIV-associated TB has much briefer mean
durations of activity and infectiousness before diagnosis than
TB in gold miners who are HIV-negative. In consequence, the
point prevalence of undiagnosed TB disease differs relatively
little between gold miners who are HIV-positive and HIV-nega-
tive, despite major differences in the risk of incident TB disease.
Our results cannot be fully or mainly explained by more intensive
follow-up of miners who are HIV-positive. Instead, we think
that they are most likely to reflect a basic difference in the natural
rate of TB disease progression between immunocompetent and
immunosuppressed individuals (7–10), resulting in more rapid
presentation and case detection for HIV-associated TB disease.
This interpretation is consistent with the otherwise unexplained
observation that the point prevalence of new radiologic TB dis-
ease has remained relatively constant during a time period when
new TB incidence rates have increased by threefold and that
the ratio of incident to prevalent cases has fallen progressively
as HIV prevalence has increased in this workforce from the
early 1990s (Figure 1).
Gold miners are an unusual population because of occupa-
tional exposure to silica dust (14), but the principle of more
rapid case detection limiting the impact of HIV on prevalent
TB disease may well be a generalizable one because rapid pro-
gression is a widely reported feature of HIV-associated TB dis-
ease (7–10). Our finding that silicosis is also associated with a
significantly reduced interval to diagnosis suggests that it may
be relatively common for risk factors that act by compromising
host defenses to also result in accelerated disease presentation.
Undiagnosed active TB can end in self-cure or death as well as
in diagnosis and treatment (17). HIV-associated immunosup-
pression may affect the absolute and relative rates at which
these alternative outcomes compete with self-presentation and
diagnosis. More rapid presentation and diagnosis are likely to
be the predominant underlying causes of the observed difference
between miners who are HIV-positive and HIV-negative in our
setting because there is both unusually intensive case finding
and a low rate of death from undiagnosed TB at this site (11,
16). In settings where diagnosis is less readily available, however,
rapid progression to death may also contribute to a relatively
short duration of infectiousness among HIV-positive persons
with TB because mortality rates are high for HIV infected TB
patients who are not promptly diagnosed, and undiagnosed TB
disease is an extremely common cause of death among HIV-
positive Africans (7–10, 17–21).
If a generalizable feature of HIV-associated TB, then a brief
duration of infectiousness would be of considerable relevance to
global TB control. The current global strategy, directly observed
therapy, short course (DOTS), is based predominantly on im-
proved case finding and treatment (22) and thus acts primarily
through control of prevalent infectious TB disease, with any falls
in TB transmission and incidence rates being achieved second-
arily (22). Evaluation and monitoring, however, are almost exclu-
sively focused on case-notification rates and treatment outcomes
(3). Alarming upward trends in TB case-notification rates have
been reported from other high HIV prevalence populations, and
the HIV epidemic is driving a global increase in incident TB
cases (3, 23). Our current results suggest that the underlying
trends in TB disease prevalence rates may be quite different
and also raise the possibility that controlling the point prevalence
of infectious TB disease may be a realistic aim of DOTS-based
TB control programs even in high HIV prevalence areas. This
would give a major boost to the prospects for global TB control
if confirmed in more typical populations because the point preva-
lence of infectious TB disease is closely correlated with the
annual risk of TB infection in any given population (24). In this
context, it is notable that stable or even declining rates of TB
transmission and TB incidence among persons who are HIV-
negative have been reported during time periods when overall
TB incidence rates have increased as a result of HIV-associated
disease from Tanzania, Cote d’Ivoire, Northern Thailand, Ma-
lawi, and this study workforce of South African gold miners
(25–29). There have also been two conflicting reports suggesting
that TB transmission has increased during the course of the HIV
epidemics in Kenya and in a different workforce of South African
gold miners (30, 31). Determining the underlying reasons for
these differences is an important challenge for all of those con-
cerned with TB control in high HIV prevalence populations.
This is the first study in which a representative sample from
a well-defined high HIV prevalence population with a high inci-
dence of TB has been recruited to investigate systematically TB
disease incidence and prevalence by HIV status. Previous studies
based in voluntary counseling and testing centers have found a
higher prevalence of active TB in clients who were HIV-positive
than clients who are HIV-negative (32–35), but are difficult to
interpret because ill-health, including symptomatic TB, is one
of the factors that motivates individuals to seek HIV testing
(35). Consequently, the prevalence of TB disease in voluntary
counseling and testing attendees will not be representative in
either HIV status group. The same self-selection effect will apply
to other healthcare settings so that trends in nososcomial TB
transmission rates during an HIV epidemic may be very different
to those in the general community.
There are a number of limitations and potential sources of
bias in this study, but none that are likely to fully account for
our main findings. A major concern in many African settings
would be underdiagnosis of incident TB; however, the study
work force has a low rate of undiagnosed TB as found at routine
postmortem (16), and all employees are screened for TB on
leaving employment. TB incidence in the retrospective element
of the cohort analysis will have been underestimated to a minor
degree by the failure to capture fatal TB episodes: case fatality
rates are, however, relatively low at this site even among patients
who are HIV-positive (36). TB incidence during the prospective
follow-up will have been reduced by the cross-sectional screen,
as prevalent patients with TB were not included as incident cases.
This will have led to overestimation of the absolute duration of
undiagnosed disease for both HIV-positive and HIV-negative
subgroups, but it avoids the otherwise implicit assumption that
in the absence of our intensive prevalence screen then all of our
prevalent patients with TB would still have been diagnosed by
the end of the prospective cohort period. We also cannot exclude
an element of ascertainment bias in the prospective incidence
data, which could be introduced if healthcare workers more
readily investigate miners who are HIV-positive for TB disease.
Our HIV-specific TB incidence rates are in the expected range
for this workforce (14), however, and our overall estimate of
point prevalence (3.8%) is similar to the prevalence of active
TB found at autopsy of miners dying from trauma (3.9% in
1991) (37). Finally, because of limited study power, we have not
considered the role of previous TB treatment, although this is
known to be a risk factor for prevalent TB disease elsewhere (24).
We have shown that HIV has a marked effect on the duration
of TB disease before diagnosis in miners. The impact of HIV
on the point prevalence of infectious TB and, by inference, on
TB transmission, is considerably less marked than the impact
on TB incidence rates. In endemic TB settings, unlike in the
United States, most TB transmission events occur between ca-
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sual contacts in the community at large (38, 39). As such, our
finding that 78% of participating miners with prevalent smear-
positive TB were HIV-negative suggests that patients who are
HIV-negative and have TB may still be responsible for the ma-
jority of TB transmission events in this community, even though
HIV prevalence in our incident patients with TB was 64%. If
correct and generalizable, then untargeted interventions to im-
prove TB control in the whole community may be the most
effective way of controlling TB transmission in high HIV preva-
lence populations and would complement strategies targeted to
known persons who are HIV-positive, such as promotion of
HIV-testing linked to antituberculous preventive therapy and
antiretroviral drugs. More generally, this study illustrates the
importance of assessing changes in the duration of infectiousness
before the likely public health consequences of risk factors for
incident infectious diseases can be fully assessed.
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